SwePub
Sök i LIBRIS databas

  Utökad sökning

id:"swepub:oai:DiVA.org:uu-389737"
 

Sökning: id:"swepub:oai:DiVA.org:uu-389737" > Influence of Proteo...

Influence of Proteome Profiles and Intracellular Drug Exposure on Differences in CYP Activity in Donor-Matched Human Liver Microsomes and Hepatocytes

Wegler, Christine (författare)
Uppsala universitet,Institutionen för farmaci,DMPK, Research and Early Development Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, 431 50 Gothenburg, Sweden,Läkemedelsformulering
Matsson, Pär, 1978- (författare)
Uppsala universitet,Institutionen för farmaci,Läkemedelsformulering
Krogstad, Veronica (författare)
Department of Pharmaceutical Biosciences, School of Pharmacy, University of Oslo
visa fler...
Urdzik, Jozef (författare)
Uppsala universitet,Gastrointestinalkirurgi
Christensen, Hege (författare)
Department of Pharmaceutical Biosciences, School of Pharmacy, University of Oslo
Andersson, Tommy B. (författare)
DMPK, Early Development Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg
Artursson, Per (författare)
Uppsala universitet,Institutionen för farmaci,Science for Life Laboratory, SciLifeLab,Läkemedelsformulering
visa färre...
 (creator_code:org_t)
2021-03-19
2021
Engelska.
Ingår i: Molecular Pharmaceutics. - : American Chemical Society (ACS). - 1543-8384 .- 1543-8392. ; 18:4, s. 1792-1805
  • Tidskriftsartikel (refereegranskat)
Abstract Ämnesord
Stäng  
  • Human liver microsomes (HLM) and human hepatocytes (HH) are important in vitro systems for studies of intrinsic drug clearance (CLint) in the liver. However, the CLint values are often in disagreement for these two systems. Here, we investigated these differences in a side-by-side comparison of drug metabolism in HLM and HH prepared from 15 matched donors. Protein expression and intracellular unbound drug concentration (Kpuu) effects on the CLint were investigated for five prototypical probe substrates (bupropion–CYP2B6, diclofenac–CYP2C9, omeprazole–CYP2C19, bufuralol–CYP2D6, and midazolam–CYP3A4). The samples were donor-matched to compensate for inter-individual variability but still showed systematic differences in CLint. Global proteomics analysis outlined differences in HLM from HH and homogenates of human liver (HL), indicating variable enrichment of ER-localized cytochrome P450 (CYP) enzymes in the HLM preparation. This suggests that the HLM may not equally and accurately capture metabolic capacity for all CYPs. Scaling CLint with CYP amounts and Kpuu could only partly explain the discordance in absolute values of CLint for the five substrates. Nevertheless, scaling with CYP amounts improved the agreement in rank order for the majority of the substrates. Other factors, such as contribution of additional enzymes and variability in the proportions of active and inactive CYP enzymes in HLM and HH, may have to be considered to avoid the use of empirical scaling factors for prediction of drug metabolism.

Ämnesord

MEDICIN OCH HÄLSOVETENSKAP  -- Medicinska och farmaceutiska grundvetenskaper -- Farmaceutiska vetenskaper (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Basic Medicine -- Pharmaceutical Sciences (hsv//eng)

Nyckelord

Human liver microsomes
Human hepatocytes
Proteomics
Kpuu
drug metabolic clearance
Pharmaceutical Science
Farmaceutisk vetenskap

Publikations- och innehållstyp

ref (ämneskategori)
art (ämneskategori)

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy